Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

July 17, 2025

CFO of Egetis Therapeutics acquires shares

Read more

Regulatory

July 15, 2025

Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency

Read more

June 16, 2025

Egetis announces exclusive distribution agreement with Er-Kim for Emcitate® in Türkiye

Read more

Upcoming event

August 21, 2025

Interim Report Q2 2025 (7:00am CEST)

Latest presentation

April 30, 2025

Interim report Q1 2025 (webcast)

Latest Report

April 30, 2025

Interim report Q1 2025

Calendar and upcoming reports

August 21, 2025

Interim Report Q2 2025 (7:00am CEST)

November 7, 2025

Interim Report Q3 2025 (7:00am CET)

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]